144 related articles for article (PubMed ID: 9200279)
1. Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease.
Engzelius JM; Solhaug JH; Knapstad LJ; Kjaersgaard P
Scand J Gastroenterol; 1997 Jun; 32(6):513-8. PubMed ID: 9200279
[TBL] [Abstract][Full Text] [Related]
2. On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets.
Johannessen T; Kristensen P
Clin Ther; 1997; 19(1):73-81. PubMed ID: 9083710
[TBL] [Abstract][Full Text] [Related]
3. Time to relief of episodic symptoms of gastro-oesophageal reflux disease. A crossover comparison of single doses of the effervescent and standard formulations of ranitidine.
Elm M; Hellke P; Andrén K; Dahl G; Nyth AL
Scand J Gastroenterol; 1998 Sep; 33(9):900-4. PubMed ID: 9759942
[TBL] [Abstract][Full Text] [Related]
4. Onset of action of antisecretory drugs: beneficial effects of a rapid increase in intragastric pH in acid reflux disease.
Pipkin GA; Mills JG
Scand J Gastroenterol Suppl; 1999; 230():3-8. PubMed ID: 10499455
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
6. The effect of ranitidine on symptom relief and quality of life of patients with gastro-oesophageal reflux disease.
Chal KL; Stacey JH; Sacks GE
Br J Clin Pract; 1995; 49(2):73-7. PubMed ID: 7779648
[TBL] [Abstract][Full Text] [Related]
7. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.
Venables TL; Newland RD; Patel AC; Hole J; Wilcock C; Turbitt ML
Scand J Gastroenterol; 1997 Oct; 32(10):965-73. PubMed ID: 9361167
[TBL] [Abstract][Full Text] [Related]
8. Gastroesophageal reflux and histamine2 antagonists.
Bell SG
Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725
[No Abstract] [Full Text] [Related]
9. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
10. [The effect of ranitidine and famotidine on the intragastric pH profile of healthy subjects. Randomized cross-over trial with ranitidine effervescent tablets (300 mg) versus famotidine film tablets (40 mg) ].
Löser C; Burlage M; Fölsch UR
Arzneimittelforschung; 1994 May; 44(5):626-9. PubMed ID: 8024636
[TBL] [Abstract][Full Text] [Related]
11. Ranitidine (Zantac) syrup versus Ranitidine effervescent tablets (Zantac) EFFERdose) in children: a single-center taste preference study.
Ameen VZ; Pobiner BF; Giguere GC; Carter EG
Paediatr Drugs; 2006; 8(4):265-70. PubMed ID: 16898856
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of oral famotidine and ranitidine on gastric volume and pH.
Dubin SA; Silverstein PI; Wakefield ML; Jense HG
Anesth Analg; 1989 Nov; 69(5):680-3. PubMed ID: 2572186
[No Abstract] [Full Text] [Related]
13. Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity.
Netzer P; Brabetz-Höfliger A; Bründler R; Flogerzi B; Hüsler J; Halter F
Aliment Pharmacol Ther; 1998 Apr; 12(4):337-42. PubMed ID: 9690722
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of increasing doses of ranitidine for treatment of heartburn.
Pappa KA; Buaron K; Payne JE; Sirgo MA; Giefer EE
Aliment Pharmacol Ther; 1999 Apr; 13(4):475-81. PubMed ID: 10215731
[TBL] [Abstract][Full Text] [Related]
15. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers.
Hedenström H; Alm C; Kraft M; Grahnén A
Aliment Pharmacol Ther; 1997 Dec; 11(6):1137-41. PubMed ID: 9663842
[TBL] [Abstract][Full Text] [Related]
16. Double-blind comparison of the safety and efficacy of famotidine with ranitidine in patients with endoscopically diagnosed peptic ulcer.
Sawant PD; Nanivadekar SA; Patel HD; Shroff CP; Oke VG; Jha RJ; Bowalekar SK; Navani SR; Raghu CN
J Assoc Physicians India; 1990 Sep; 38 Suppl 1():723-6. PubMed ID: 2092029
[TBL] [Abstract][Full Text] [Related]
17. Are frequent short gastro-oesophageal reflux episodes the cause of symptoms in patients with non-ulcer dyspepsia responding to treatment with ranitidine?
Farup PG; Hovde O; Breder O
Scand J Gastroenterol; 1995 Sep; 30(9):829-32. PubMed ID: 8578179
[TBL] [Abstract][Full Text] [Related]
18. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
19. Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis.
Hatlebakk JG; Berstad A
Scand J Gastroenterol; 1996 Oct; 31(10):954-8. PubMed ID: 8898414
[TBL] [Abstract][Full Text] [Related]
20. Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis.
Fiorucci S; Santucci L; Perrone E; Abbritti F; Morelli A
Scand J Gastroenterol; 1989 Aug; 24(6):671-7. PubMed ID: 2573143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
